AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

[News]

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

More... (http://www.news-medical.net/news/20101202/AVEO-to-present-data-on-tivozanib-Phase-1b-trial-for-breast-cancer-at-SABCS-Symposium.aspx)